Vectura Group的动态

Thoughts on this? >> Biovance debuts with €51M to lift up biotech scene in Portugal and southern Europe >> Comment below! >>> lqventures.com #strategy #competitiveintelligence #marketing #biotech #pharma #healthcare #pharmaceutical #productmarketing

With ustekinumab biosimilars set to launch in Europe imminently and in the US early next year, the off-patent industry may be wondering whether it will be in for a rerun of its experiences with competition on Humira – or whether the landscape has changed sufficiently to allow for different pricing and uptake trends.?Generics Bulletin?looks at the expectations of a host of industry leaders.

?? Nutriband Q3 Results Nutriband (Nasdaq: NTRB) advances its abuse-deterrent transdermal patch towards New Drug Application submission in 2025. ?? Revenue up 51% YoY, retail gains boost future outlook. ?? Details here: https://lnkd.in/eQBHAEEJ #Biotech #HealthcareInnovation #MedicalBreakthrough #ClinicalTrials #transdermal #HealthTech #DrugDevelopment #MedTech #LifeSciences

How are EDDOs (Essential Drug Delivery Outputs) determined during the design of a drug-led or biologic-led combination product? In this segment from Drug Delivery Leader Live, consultant Susan Neadle lays out the foundational considerations. https://lnkd.in/edmJRR9M

?? Clinical Trials Roundup: Tracking the “COVID Effect” on Trial Initiations ?? Over the last three editions of Citeline's Clinical Trials Roundup, we've closely monitored the impact of the pandemic on clinical trial initiations across all therapeutic areas (TAs). The "COVID effect" brought dramatic fluctuations: ?? 2020: A -4% decline due to the global disruption. ?? 2021: A surprising +22% recovery. ?? 2022: A -6% dip driven by biopharma’s tough economic environment. Now in 2023, the yo-yo has swung back up, showing 13% growth—excluding COVID-19 trials—well above the 7% average growth seen from 2017–2023 for non-COVID trials. Is the industry set for continued recovery, or will we see more cycles of growth and decline? Stay tuned as we continue to track this dynamic landscape! ?? #ClinicalTrials #Pharma #Biotech #COVIDEffect #Citeline #HealthcareInnovation #ClinicalResearch #Recovery

Thoughts on this? >> Triveni to take experimental eczema drug to the clinic, backed by new $115M financing round >> Comment below! >>> lqventures.com #strategy #competitiveintelligence #marketing #pharma #pharmaceutical #healthcare #biotech #productmarketing

June's Controlled & Modified Drug Release / Bioavailability Enhancement program is viewable on the below link. 2024’s Summit themes include: - Long acting injectables? - Solubilization approaches for parenteral routes of administration - Innovations in oral modified release technologies - Advances in oral delivery of peptides - PBPK Modeling to drive product development? - Engineering prodrug therapies for infectious disease and cancer therapy - Excipients selection and understanding impact on oral drug bioavailability - Lipid-based formulations - Enhancing API bioavailability via nanotechnology for drug delivery - Innovations in targeted drug delivery mechanisms - Optimizing biologics product development - Improving oral bioavailability for poorly-soluble drug candidates - Patent-centric formulation approaches - Subcutaneous delivery - Advances wearable drug delivery systems And many more drug product development technologies and approaches.

Pharsights Business Solutions aims to reduce the time it takes to market medicines, benefiting people and increasing the flow of new medicines into the market. Founder Ritesh Udhani has channelled his 15 years of experience in the pharma industry into understanding problems and catering to them via Pharsights. Watch to know how Pharsights is changing the game in the evolving pharma market. #THubFounderTalks #InnovateWithTHub #InnovationEcosystem Chandra Kumar N

Lumi & CatSci Ltd to enhance medicines manufacturing and reduce time-to-market with Innovate UK-backed advanced approach for lab data capture & processing: https://lnkd.in/ezhs3wFf With support from Innovate UK, our advanced approach to lab data capture and processing is set to reduce time-to-market and improve workflow efficiency. ?In this project, we are moving a step forward to develop a system for scale-up labs to monitor oligonucleotide production and accurately track critical steps in medicines manufacturing, where subtle process changes could result in significant material and time loss. Success in this project will represent a productivity boost of up to 40% for CatSci, especially in the #oligonucleotide manufacturing pathway. In the longer term, we expect that Lumi users can demonstrate reduced waste from both manufacturing and scale-up processes; a significant benefit in #NetZero and #sustainability. By reducing time in scale-up, it reduces time-to-market for new products. In turn this increases patient access to medicines. Follow the link to read the full release and learn more about the project: https://lnkd.in/ezhs3wFf

Thoughts on this? >> Biohaven’s $230M offering; Plus, three new PIPEs >> Comment below! >>> lqventures.com #strategy #competitiveintelligence #marketing #healthcare #biotech #productmarketing #pharma #pharmaceutical